The United States National Institutes of Health (NIH) has long maintained a global network of research partnerships, distributing billions of dollars in taxpayer-funded grants to international institutions. While these grants are intended to foster scientific advancement and address global health crises, a growing body of evidence suggests that a significant portion of this funding supports invasive and controversial animal experiments in foreign laboratories. These facilities, operating outside the direct jurisdiction of U.S. federal inspectors, have become the focus of intense legislative scrutiny following reports of extreme animal suffering and questionable scientific utility. At the center of this debate is the Cease Animal Research Grants Overseas (CARGO) Act, currently identified as HR 1085 and S 1802, which seeks to terminate NIH funding for animal experiments conducted in foreign countries.
The scope of this funding is vast, involving millions of dollars annually directed toward experiments ranging from addiction studies in Australia to invasive neurological procedures in Europe and infectious disease modeling in South America and Africa. Proponents of the CARGO Act argue that these expenditures not only represent a fiscal burden on American taxpayers but also bypass the rigorous welfare standards mandated for domestic laboratories. Because the U.S. Department of Agriculture (USDA) does not inspect foreign facilities, oversight is largely reliant on self-reporting and "letters of assurance," a system critics describe as fundamentally flawed.
The Legislative Context: The CARGO Act
The Cease Animal Research Grants Overseas (CARGO) Act was introduced in response to mounting concerns regarding the lack of accountability for NIH-funded international projects. The bill, which enjoys bipartisan support, aims to amend the Public Health Service Act to prohibit the NIH from providing funding for any project that involves testing on animals if that project is conducted outside the United States.
The primary arguments for the legislation are twofold: financial accountability and ethical oversight. Domestic laboratories in the U.S. are subject to the Animal Welfare Act (AWA) and regular inspections by the USDA’s Animal and Plant Health Inspection Service (APHIS). However, foreign laboratories are exempt from these specific federal inspections. While the NIH’s Office of Laboratory Animal Welfare (OLAW) requires foreign grantees to follow certain guidelines, the inability of U.S. officials to conduct unannounced on-site inspections creates a transparency gap. Legislative sponsors argue that by redirecting these millions of dollars to domestic research—particularly non-animal, human-relevant models—the U.S. can better ensure both scientific rigor and humane treatment.
Case Studies in International Funding: Australia and Canada
Australia has been a major recipient of NIH funding for diverse animal models. Between 2019 and 2024, Kinoxis Therapeutics received $5,952,408 from the National Institute on Drug Abuse to test molecules for opioid withdrawal. The methodology involved forcing 1,485 mice, 314 rats, and 80 beagles into states of opioid addiction. Critics point to the high failure rate of translating addiction treatments from canine and rodent models to human clinical success as a reason to question the nearly $6 million price tag.
In another Australian study at the Walter and Eliza Hall Institute of Medical Research, funded by the National Institute of Allergy and Infectious Diseases (NIAID), experimenters were granted over $1.5 million to infect animals with toxoplasmosis. This disease, which causes fever, diarrhea, and seizures, is studied globally, yet the necessity of funding such invasive work abroad remains a point of contention. Other Australian projects included infecting bats with harmful viruses at the Commonwealth Scientific and Industrial Research Organization (CSIRO) and tuberculosis infections in monkeys at the University of Sydney, the latter costing over $8.1 million.
Canada presents an even more extensive portfolio of NIH-funded animal research. The University Health Network (UHN) in Toronto has received multiple grants, including $3,771,814 for stroke research involving rats and monkeys. Reports indicate that these animals suffered brain hemorrhages and high mortality rates within 24 hours of the procedures. Furthermore, UHN received over $1.1 million for xenotransplantation experiments involving pig lung transplants. These experiments involve "donor" pigs being euthanized for their organs, which are then transplanted into "recipient" pigs. Despite decades of such research, xenotransplantation has yet to provide a viable, long-term solution for human organ shortages, leading many to label the continued funding as a "sunk cost" fallacy.
At McGill University, a project funded by the National Institute on Deafness and Other Communication Disorders (NIDCD) utilized $6,512,269 between 2008 and 2025. This study involved cutting the vocal cords of rabbits and using spatulas to intentionally exacerbate scarring and inflammation to ensure "adequate injury" for observation.
Neurological and Behavioral Experiments in Europe
European institutions, despite stringent regional regulations like the EU Directive 2010/63/EU, also receive substantial NIH support for highly invasive procedures. In Finland, the University of Helsinki received over $422,000 to implant more than 500 electrodes into the brains of fully awake rats, forcing them to live with the implants for months to monitor neurological activity.
In Sweden, the Karolinska Institute—a prestigious medical university—has been a frequent beneficiary of NIH grants. One project, totaling $3,482,020, involved surgically implanting electrodes into the legs of rabbits before severing their spinal cords. In other procedures at the same institute, mice were injected with brain-inflaming substances and exposed to intense noise before being euthanized. Additionally, the institute received over $2 million to study the effects of aspartame on mice of varying ages, a study that concluded with the killing of the animals at specific month intervals.
The United Kingdom also maintains a strong pipeline of NIH funding. Newcastle University received $1,819,429 for stroke experiments on monkeys, which involved implanting electrodes into their arms and intentionally damaging their brains to induce paralysis. University College London (UCL) is slated to receive nearly $800,000 in 2025 to develop abnormal proteins in the brains of mice to simulate neurodegenerative diseases.
Oversight Failures and Ethical Violations in the Global South
Perhaps the most significant evidence cited by proponents of the CARGO Act involves research conducted in countries where animal welfare infrastructure is less robust. In Colombia, the Caucaseco Scientific Research Center and the Malaria Vaccine and Development Center received over $17.6 million between 2003 and 2023. Investigations into these facilities revealed a pattern of neglect; monkeys and mice infected with malaria were reportedly abandoned in filthy, substandard cages and denied basic veterinary care. This case became a catalyst for the CARGO Act, as it demonstrated that the NIH was unable to prevent gross animal welfare violations at a facility it had funded for two decades.
In Chile, the Universidad de Concepción received $2,380,836 for alcohol addiction studies. These experiments involved injecting alcohol into the abdominal cavities of mice and subjecting them to behavioral tests, such as the "tail suspension test," to measure their panicked responses. Critics argue that the physiological and psychological response of a mouse to being suspended by its tail while intoxicated offers little to no relevant data for treating complex human alcoholism.
Similar patterns are seen in Africa and Asia. In Kenya, Kenyatta University received $629,696 to infect hamsters with schistosomiasis, a debilitating parasitic disease. In Nigeria, the Federal University of Technology was granted nearly $400,000 for studies where rats were fed specialized diets before having their bladders surgically removed. In India, the Indian Institute of Science used $241,992 to genetically modify mice to suffer from chronic diarrhea and gut inflammation.
Financial Breakdown and Taxpayer Impact
The cumulative cost of these international grants is staggering. Based on a sampling of NIH data from the last decade, the projects listed above represent an expenditure of over $60 million. However, this is only a fraction of the total international animal research budget. According to fiscal transparency advocates, the NIH spends an estimated $300 million to $500 million annually on foreign grants involving animal models.
The "Price Tags" associated with these experiments often include high indirect costs (administrative fees) that are paid to foreign universities, money that critics argue should stay within the U.S. economy. Furthermore, the lack of "return on investment" is a frequent point of criticism. In many of the cases cited, such as the typhus infections in monkeys in St. Kitts (costing $104,932) or the use of rabbits as sandfly bait in Tunisia ($249,977), the research has not resulted in breakthroughs that significantly alter the trajectory of human medicine.
Scientific Critique and the Reproducibility Crisis
Beyond the ethical and financial concerns lies a fundamental scientific question: are these animal models effective? The biomedical community is currently grappling with a "reproducibility crisis," where results from animal studies frequently fail to replicate in human clinical trials. Data suggests that approximately 90% of drugs that pass animal testing fail when they reach human subjects, often due to unforeseen toxicity or lack of efficacy.
The CARGO Act aligns with a broader movement toward "New Approach Methodologies" (NAMs). These include organ-on-a-chip technology, sophisticated computer modeling, and human-cell-based research. Proponents argue that if the NIH redirected the millions spent on foreign animal labs toward these modern technologies, the U.S. would likely see a higher rate of medical success.
Official Responses and Implications
The NIH has historically defended its international grants, stating that global collaboration is essential for tackling diseases that do not respect national borders, such as malaria, tuberculosis, and emerging viral threats. They contend that foreign institutions often provide unique environments or access to specific species that are necessary for certain types of research.
However, the political tide appears to be shifting. The introduction of the CARGO Act in both the House and the Senate reflects a growing appetite for stricter oversight of federal spending. If passed, the act would force a massive restructuring of the NIH’s international portfolio. It would also send a clear signal to the global scientific community that U.S. funding is contingent upon the highest levels of transparency and the prioritization of human-relevant research methods.
The implications of the CARGO Act extend beyond animal welfare. It touches on themes of national sovereignty, fiscal responsibility, and the evolution of 21st-century science. As the debate continues in Congress, the focus remains on whether the current system of "outsourcing" animal experimentation is a necessary component of medical progress or an outdated practice that wastes taxpayer resources while inflicting unnecessary suffering on thousands of animals across the globe. For now, the millions of dollars continue to flow to laboratories from Australia to Nigeria, while the animals within them remain subject to procedures that would, in many cases, be under intense scrutiny if they were performed on American soil.
